Paul G. Allen Frontiers Group [to 26 Sep 2020]
SCANning for coronavirus
The SCAN study launched to track Covid-19 in the Seattle area led by Allen Discovery Center leader Dr. Jay Shendure
September 23, 2020


BARDA – U.S. Department of HHS [to 26 Sep 2020]
No new digest content identified.


BMGF – Gates Foundation [to 26 Sep 2020]
SEPTEMBER 21, 2020
Gates Foundation Honors Director of Africa CDC With 2020 Global Goalkeeper Award
Foundation also announces three Global Goals award winners and launches two innovative partnerships to address COVID-19 impacts in Kenya
…“Dr. Nkengasong and his team at Africa CDC are deeply deserving of this award,” said Bill Gates, co-chair of the Bill & Melinda Gates Foundation. “Their commitment to securing the latest innovations from elsewhere in the world—as well as developing them themselves—will go a long way towards ensuring that the continent has the vaccines and medicines it needs to fight COVID-19.”
In addition to Dr. Nkengasong, this year’s awards went to Hauwa Ojeifo of Nigeria, Bonita Sharma of Nepal, and the MASH Project Foundation based in India. Each was recognized for playing a role in addressing the effects of COVID-19 in their communities. More details about each of the awards and their winners follows…


Bill & Melinda Gates Medical Research Institute [to 26 Sep 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 26 Sep 2020]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
09.22.2020  |
CARB-X funds GSK to develop a new drug for urinary tract infections (UTI) caused by Escherichia coli bacteria
CARB-X is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop a new drug to treat and prevent recurrent urinary tract infections (UTIs) caused by the Escherichia coli (E. coli) bacteria.


CEPI – Coalition for Epidemic Preparedness Innovations [to 26 Sep 2020]
Latest News
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility
21 Sep 2020
> 64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
> These self-financing economies, which include 29 from ‘Team Europe’ participating as part of an agreement with the European Commission, join 92 lower income economies eligible for financial support through the Gavi COVAX Advance Market Commitment
> This means a total of 156 economies, representing nearly two-thirds of the global population, are now committed to or eligible to receive vaccines through the Facility Click here for the list of economies


EDCTP [to 26 Sep 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 26 Sep 2020]
Vaccine Center News
No new digest content identified.


European Medicines Agency [to 26 Sep 2020]
News & Press Releases
News: Guideline on registry-based studies – launch of public consultation
Last updated: 24/09/2020
EMA has published its draft  Guideline on registry-based studies for a three-month public consultation today. The new draft guidance aims to optimise the use of registry-based studies as a source of real-world evidence.
Patient registries are databases containing quantitative and qualitative data about patients who are affected by a particular condition.
The guideline addresses methodological, legal and operational aspects in the use of registry-based studies to support regulatory decision-making.Stakeholders are invited to send their comments via a online form by 31 December 2020…


European Vaccine Initiative [to 26 Sep 2020]
Latest News
No new digest content identified.


FDA [to 26 Sep 2020]
Press Announcements
September 25, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 25, 2020
:: The FDA issued an updated FDA COVID-19 Response At-A-Glance Summary which provides a quick look at facts, figures and highlights of the agency’s response efforts.
Testing updates:
:: As of today, 255 tests are authorized by FDA under EUAs; these include 204 molecular tests, 47 antibody tests, and 4 antigen tests.

September 24, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 24, 2020
:: FDA developed new health education materials that have been culturally and linguistically tailored for diverse consumers. These materials are intended for health care professionals to share with their patients to help stimulate dialogue and answer pressing questions about FDA’s response to COVID-19. The materials provide information on the different areas of the FDA’s response to the pandemic, including health fraud, medical product supply, therapeutics, vaccine development, and diagnostic and antibody testing.

September 23, 2020 – Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19

September 23, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 23, 2020
:: FDA Commissioner Stephen M. Hahn, M.D., testified before the Senate Committee on Health, Education, Labor and Pensions at a hearing entitled, “COVID-19: An Update on the Federal Response.”
:: FDA today posted a document summarizing updated evidence to support the emergency use of COVID-19 Convalescent Plasma. The agency will continue to review the circumstances and appropriateness of the authorization for emergency use. To make this information accessible to the public, the document posted on the web presents FDA’s review in relatively plain language.

September 22, 2020 – FDA Launches the Digital Health Center of Excellence
Today, the U.S. Food and Drug Administration announced it is launching the Digital Health Center of Excellence within the Center for Devices and Radiological Health (CDRH). The launch of the Digital Health Center of Excellence is an important step in furthering the agency’s overarching dedication to the advancement of digital health technology, including mobile health devices, Software as a Medical Device (SaMD), wearables when used as a medical device, and technologies used to study medical products…

September 21, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 21, 2020
:: A new video entitled, Beware of Fraudulent Coronavirus Tests, Vaccines and TreatmentsExternal Link Disclaimer, explains to consumers that there are currently no FDA-approved drugs or vaccines to treat or prevent COVID-19. Products that fraudulently claim to cure, treat, diagnose, or prevent COVID-19 haven’t been evaluated by the FDA for safety and effectiveness for such use, and they might be dangerous to you and your family.
:: The FDA has added content to the question-and-answer appendix in its guidance titled “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency.” The updated guidance includes a new question-and-answer regarding a clinical trial investigator’s responsibility to review all investigational new drug application safety reports, including reports that will not result in a change to the investigator brochure, informed consent, or protocol.


Fondation Merieux [to 26 Sep 2020]
News, Events
Rodolphe Mérieux Laboratory
Training at the Rodolphe Mérieux Laboratory in Goma, a key player in the fight against COVID-19 in the DRC
September 25, 2020 – DRC
From September 8 to 15, the team at the Rodolphe Mérieux Laboratory of the National Institute of Biomedical Research (INRB) in Goma, and staff from the INRB in Kinshasa, received training on diagnostic testing, including COVID-19, from Mérieux Foundation experts


Gavi [to 26 Sep 2020]
News releases
25 September 2020
Experimental approaches to address post-transition risks
After transitioning out of Gavi support in 2017, the Republic of Moldova is mobilising champions and advocates to strengthen vaccine confidence – which is crucial to the success and sustainability of immunisation programmes.

24 September 2020
Typhoid: immunising against antimicrobial resistance
In November 2019, Pakistan took a big step forward to protect future generations when it became the first country to introduce typhoid conjugate vaccine (TCV) into its routine immunisation programme. Spread through contaminated food and water, typhoid is a preventable disease that disproportionately affects young people and under-served communities in Asia and sub-Saharan Africa. It is often associated with poorer urban areas where there is little access to sanitation or clean water…

23 September 2020
Gavi at UNGA: Global solidarity to defeat COVID-19 and create a better world for all
September 2020 marks the 75th anniversary of the United Nations General Assembly (UNGA). This year, the focus of the high-level General Debate is the importance of effective multilateralism: “The future we want, the United Nations we need: reaffirming our collective commitment to multilateralism – confronting COVID-19 through effective multilateral action.”
A typically very busy time of the year at the UN Headquarters in New York is reimagined as a series of virtual discussions, with COVID-19 high on the agenda – as economies continue to grapple with the health, social and economic fallout from the crisis, and its impact on the Sustainable Development Goals. Being a central player in the COVID-19 response as a co-lead of COVAX, Gavi is working to end the acute phase of the pandemic through urgent and collaborative action…


GHIT Fund [to 26 Sep 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 26 Sep 2020]
No new digest content identified.


Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 26 Sep 2020]
No new digest content identified.


Hilleman Laboratories [to 26 Sep 2020]
No new digest content identified.


Human Vaccines Project [to 26 Sep 2020]
Press Releases, Events
Global COVID Lab Meeting
The Next Great Frontier: COVID Vaccine Development
Oct 01, 2020

Global COVID Lab Meeting
October 8th speaker: Emanuele Andreano
Oct 08, 2020


IAVI [to 26 Sep 2020]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics (24 September 2020)
Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (Biodrugs), the International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today released a new policy paper:
Developing a Regulatory Framework Supporting Biosimilar Competition: The Opportunity for Tailored Clinical Biosimilar Development



No new digest content identified.


IFRC [to 26 Sep 2020]
Selected Press Releases, Announcements
At least 51.6 million people doubly hit by climate-related disasters and COVID-19, new analysis by IFRC reveals
New York, Geneva, 23 September 2020 – New analysis published today by the International Federation of Red Cross and Red Crescent Societies (IFRC) and the Red Cross Red Crescent Climate Centre reveals that at least 51.6 million people worldwide have bee …
23 September 2020


IRC International Rescue Committee [to 26 Sep 2020]
Media highlights [Selected]
Press Release
25 Years Following the Beijing Platform for Action Finds Widening Gaps in Gender Equality for Women and Girls in Conflict Settings
September 24, 2020

Press Release
Deadly malaria and cholera outbreaks grow amongst refugees as COVID pandemic strains health systems, warns IRC
September 22, 2020

Press Release
As the U.S. reaches 200,000 COVID-19 deaths, IRC expresses concern for U.S. ability to protect vulnerable populations at home and abroad
September 20, 2020


IVAC [to 26 Sep 2020]
Updates; Events
No new digest content identified.


IVI [to 26 Sep 2020]
Selected IVI News & Announcements
No new digest content identified.


JEE Alliance [to 26 Sep 2020]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 26 Sep 2020]
Latest [Selected Announcements]
COVID-19 outbreak in Baghdad is “very alarming”
Project Update 24 Sep 2020

South Sudan
Heavy floods threaten the lives of thousands of people in Greater Pibor
Project Update 23 Sep 2020

Coronavirus COVID-19 pandemic
Ten-fold increase in COVID-19 cases adds new challenges in northwest S…
Project Update 22 Sep 2020

Tackling COVID-19 in Hebron, the epicentre of the outbreak in Palestine
Project Update 21 Sep 2020

Coronavirus COVID-19 pandemic
COVID-19 and rural South Africa 21 Sep 2020


National Vaccine Program Office – U.S. HHS [to 26 Sep 2020]\
NVAC Meetings
September 23, 2020 – September 24, 2020
This meeting was held virtually.


NIH [to 26 Sep 2020]
Selected News Releases
Scientists discover genetic and immunologic underpinnings of some cases of severe COVID-19
September 24, 2020 — NIH investigator co-led international research effort.
New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19.

The researchers found that more than 10% of people who develop severe COVID-19 have misguided antibodies―autoantibodies―that attack the immune system rather than the virus that causes the disease. Another 3.5% or more of people who develop severe COVID-19 carry a specific kind of genetic mutation that impacts immunity. Consequently, both groups lack effective immune responses that depend on type I interferon, a set of 17 proteins crucial for protecting cells and the body from viruses. Whether these proteins have been neutralized by autoantibodies or―because of a faulty gene―were produced in insufficient amounts or induced an inadequate antiviral response, their absence appears to be a commonality among a subgroup of people who suffer from life-threatening COVID-19 pneumonia.

These findings are the first published results from the COVID Human Genetic Effort(link is external), an international project spanning more than 50 genetic sequencing hubs and hundreds of hospitals. The effort is co-led by Helen Su, M.D., Ph.D., a senior investigator at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH; and Jean-Laurent Casanova, M.D., Ph.D., head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University in New York. Major contributions were made by Luigi Notarangelo, M.D., chief of the NIAID Laboratory of Clinical Immunology and Microbiology (LCIM); Steven Holland, M.D., director of the NIAID Division of Intramural Research and senior investigator in the NIAID LCIM; clinicians and investigators in hospitals in the Italian cities of Brescia, Monza and Pavia, which were heavily hit by COVID-19; and researchers at the Uniformed Services University of the Health Sciences in Bethesda, Maryland…

Fourth large-scale COVID-19 vaccine trial begins in the United States
September 23, 2020 — Trial evaluating investigational Janssen COVID-19 vaccine.
[See COVID-19 above for detail]

NIH expands clinical trials to test convalescent plasma against COVID-19
September 22, 2020 — Rigorous studies to build on earlier efforts to test the experimental treatment
Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19. Preliminary observational studies indicate that convalescent plasma may improve outcomes among severely ill and hospitalized patients with COVID-19. Prospective, well-controlled randomized trials are needed to generate sufficient data on whether convalescent plasma is effective and safe for the treatment of COVID-19…


PATH [to 26 Sep 2020]
Press Releases
No new digest content identified.


Sabin Vaccine Institute [to 26 Sep 2020]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 26 Sep 2020]
Selected Press Releases/Reports/Statements
25 September 2020
HIV recency testing programme launched in eastern Europe and central Asia

24 September 2020
How the Jamaica transgender community is surviving COVID-19

22 September 2020
By any means necessary: defending human rights in Uganda in the time of COVID-19

21 September 2020
“Physical distance, not social distance”: supporting Jamaican women living with HIV during COVID-19

21 September 2020
90–90–90: good progress, but the world is off-track for hitting the 2020 targets


UNICEF [to 26 Sep 2020]
Press release
Remarks by Henrietta Fore, UNICEF Executive Director, at the launch of the Every Woman Every Child Progress report [delivered on her behalf by Omar Abdi, Deputy Executive Director for Programmes]

Press release
Conflict, climate crisis and COVID-19 pose great threats to the health of women and children

As classrooms for half the world’s schoolchildren remain closed, UNICEF and EU urge countries to prioritize schools in re-opening plans
Statement by EU High Representative for Foreign Affairs and Security Policy Josep Borrell, EU Vice-President Dubravka Šuica, and UNICEF Executive Director Henrietta Fore on the occasion of Digital Cooperation Action Day at the UN General Assembly, and ahe

Managing the COVID-19 infodemic: Promoting healthy behaviours and mitigating the harm from misinformation and disinformation
Joint statement by WHO, UN, UNICEF, UNDP, UNESCO, UNAIDS, ITU, UN Global Pulse, and IFRC

Press release
COVID-19 pandemic: countries urged to take stronger action to stop spread of harmful information

Statement by UNICEF Executive Director Henrietta Fore on the European Commission’s proposed Pact on Migration and Asylum

Press release
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days

Press release
Time to re-open schools in Eastern & Southern Africa, as the cost for children escalates in learning, protection and nutrition


Unitaid [to 26 Sep 2020]
Featured News
No new digest content identified.


Vaccination Acceptance Research Network (VARN) [to 26 Sep 2020]
No new digest content identified.


Vaccine Confidence Project [to 26 Sep 2020]
Research and Reports
Online Event: CSIS Book Launch with Heidi J. Larson – Stuck
19 Sep 2020


Vaccine Education Center – Children’s Hospital of Philadelphia [to 26 Sep 2020]
September 2020
Vaccine Update for Providers
:: Announcements: Updated VEC materials
:: Recent interviews with Dr. Offit
While Dr. Offit has been busy giving a variety of interviews, a couple of recent conversations may be of particular interest:
The Race to a COVID-19 Vaccine with Dr. Paul Offit, University of Pennsylvania, Perry World House, Sept. 1, 2020
Paul Offit’s Biggest Concern about COVID Vaccines, Medscape, Sept. 9, 2020
The VEC’s Current Issues in Vaccines webinar, “Making a COVID-19 Vaccine at Warp Speed,” scheduled for noon ET on Sept. 23 and will be archived on this page by Sept. 25.
:: News & views – COVID-19 and kids — What do we know?
Charlotte A. Moser, Assistant Director, and Paul A. Offit, Director, Vaccine Education Center at Children’s Hospital of Philadelphia


Wellcome Trust [to 26 Sep 2020]
Explainer | 25 September 2020
What are human infection studies and why do we need them?
Human infection studies (also known as human challenge trials and controlled human infection models) have the power to rapidly accelerate the development of much-needed vaccines and treatments, including for Covid-19.

Explainer | 23 September 2020
From equality to global poverty: how Covid-19 is affecting societies and economies
The Covid-19 pandemic is a social and an economic crisis just as much as it is a health crisis – its repercussions, severe and far-reaching, are being felt across the world.


The Wistar Institute [to 26 Sep 2020]
Press Releases
No new digest content identified.


WFPHA: World Federation of Public Health Associations [to 26 Sep 2020]
Latest News
No new digest content identified.


World Organisation for Animal Health (OIE) [to 26 Sep 2020]
Press Releases
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 26 Sep 2020]
Press Releases
No new digest content identified.


BIO [to 26 Sep 2020]
Press Releases
BIO Presents Leadership and Legacy Award to Sharon Bomer Lauritsen
Washington, D.C. (September 22, 2020) –The Biotechnology Innovation Organization (BIO) today presented Sharon Bomer Lauritsen, founder of AgTrade Strategies LLC, former Assistant United States Trade Representative for Agricultural Affairs and Commodity Policy, and a past leader of BIO’s Food and Agriculture Section, with the fifth annual BIO Leadership and Legacy Award.


DCVMN – Developing Country Vaccine Manufacturers Network [to 26 Sep 2020]
News; Upcoming events
No new digest content identified.


ICBA – International Council of Biotechnology Associations [to 26 Sep 2020]
No new digest content identified.


IFPMA [to 26 Sep 2020]
Selected Press Releases, Statements, Publications
Innovative health industries united in welcoming UNGA Resolution on “Comprehensive and Coordinated Response to the COVID-19 Pandemic
22 September 2020
Joint Statement – Global Innovative Health Industries Alliance
Innovative health industries united in welcoming United Nations General Assembly Resolution on “Comprehensive and Coordinated Response to the COVID-19 Pandemic “
On behalf of global biopharmaceutical and medical technologies companies, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the International Council of Biotechnology Associations (ICBA), the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), and the Global Self-Care Federation (GSCF) welcome the adoption of Omnibus Resolution [1]highlighting the need for global response and effective international cooperation to ensure that no one is left behind in the race against COVID-19.


We share the view that a well-coordinated, inclusive, multi-stakeholder approach and solidarity are the only possible solutions to help solve the COVID-19 global public health emergency. We welcome the encouragement expressed in the Resolution to cooperate with the private sector, and to promote public-private partnerships to contain, mitigate and defeat the pandemic and its consequences, including by exchanging information, scientific knowledge and best practices. As WHO’s Director General recently stated, “the private sector has an essential role to play in combating this public health crisis through their expertise, innovation, and resources.” We believe that being an equal partner in all coordination efforts and actively participating in multi-stakeholder’ platforms is the only way forward.


We fully endorse the call to put in place a whole of government and whole of society response, with a view to sustainably strengthening the health system, social care and support systems, preparedness, and response capacities, engaging with communities and collaborating with relevant stakeholders. This pandemic showed that strengthening health systems, effective emergency preparedness, and ensure continued investments in global health are measures of critical importance. Our members are working to secure the continuity of supply for all essential medicines, and vaccines for patients with other life-threatening diseases, urging governments to implement policies and decisions that facilitate access for all those in need.


We reaffirm our commitment as an essential partner, in terms of investing in medicines, vaccines and medical technologies development and pursuing approaches to expand access, equal and fair distribution of solutions globally. Since the early days of this pandemic, private sector stakeholders responded through many initiatives aimed at providing and prioritizing delivery of needed critical products to tackle COVID-19 while also addressing research and development of innovative health technologies including preventive tools, diagnostics, treatment, medicines, and vaccines, motivated by a strong sense of responsibility to act together, in partnership with WHO and governments, to support health systems across the world in a concerted and collective response. Access to COVID-19 vaccines is a collective responsibility that calls for highly coordinated and collaborative action by public and private actors’ alike and global solidarity to solve the COVID-19 pandemic. We are fully supportive of the work of the ACT-Accelerator and fully committed to the goals of the COVAX pillar to accelerate development, production, and equitable access to safe, quality effective COVID-19 vaccines, leaving no one behind.

The decades-long investments our industries have made in new technology research, underpinned by sound intellectual property protection, have prepared us to act swiftly to respond to the crisis. Our member companies are pushing the boundaries of science, developing workable solutions, and ensuring there is capacity to scale up. They are also re-directing manufacture of urgently needed products once solutions are found, while at the same time, ensuring continuity of global supply for critical products.

Focusing on these critical components, including reinforcing the mindset of systems thinking and international cooperation, will better prepare and equip our societies for future crises. Regular communication and coordination between governments and industry is the fastest and surest path to success. A strong partnership is essential now, and in the weeks and months to come.

Finally we would like to underline the full recognition given in the resolution for the critical role of and efforts made by health workers, and other frontline and essential workers, including humanitarian personnel, around the world aimed at addressing the pandemic through measures to protect the health, safety and well-being of people. Their remarkable work should serve as motivation for others who are key for tackling this pandemic.

We look forward to continuing good cooperation and collaboration with all relevant stakeholders and welcome the adoption of this overarching resolution as an impetus to strive for an open channel of communication and to working constructively to overcome obstacles and promote timely access to prevention, diagnosis, treatment and after care.
[1] A/RES/74/306

Innovative vaccine and medicine industry applaud country commitments to COVAX Facility
21 September 2020
Vaccine makers, and biopharmaceutical industry more generally, are encouraged to see the broad international support the COVAX Facility has received today.


The 156 economies committed to participate in the Facility, including 64 higher income economies, represent the best chance the world has to ensure that by 2021, 64% of the global population has access to safe and effective COVID-19 vaccines. In so doing, wealthier countries are showing their solidarity towards others. Vaccine makers reaffirm their unstinting support for this most ambitious pandemic-response initiative ever conceived.


IFPMA, the body representing the biopharmaceutical industry globally is a founding member of the ACT-Accelerator of which the COVID-19 Vaccine Global Access Facility (COVAX) is a key pillar. The vaccine industry has a seat at the table in acknowledgement of the industry’s key role in research, development and its expertise in being able to scale up manufacturing to unprecedented levels.

“It is very encouraging to see so many countries move from talk to full commitment. The Facility can only work, and equitable access can only be achieved, if there is solidarity between rich and poorer countries. Today vaccine makers who have the unique skills and expertise to scale up manufacturing to levels never seen before, stand ready, together, to take up the challenge of providing two billion doses of yet unknown COVID-19 vaccines. This is no mean feat, as it requires doubling existing capacity in record time. Today, marks a significant step forward, and is a historic mark of solidarity which has the power to bring the acute phase of this pandemic to an end; and we are proud to be part of this unique endeavour to leave no one behind” said Thomas Cueni, Director General of the IFPMA.

From day one, vaccine makers have stepped up in an unprecedented manner, with leading innovative companies devoting resources, expertise, know-how and intellectual assets to developing potential vaccines. However, we are deeply aware that science and innovation are only part of the equation. As part of our responsibility towards society, we must also ensure equitable global access to safe, high quality, effective, and affordable COVID-19 vaccines. This is why it is so important to partner with multilateral organizations like the WHO and Gavi, the Vaccine Alliance and CEPI to identify the global need and, along with donor governments and philanthropic foundations, address the unique challenges faced by low-income and middle-income countries.


COVID-19 is cruelly driving home a tough lesson: facing any global health challenge, in particular of such unprecedented scale, requires solidarity and inclusive cooperation. Governments are all understandably eager to protect their citizens, and their investments have contributed to the much-needed acceleration of development and upscaling of manufacturing capacity that the world needs.

The COVAX Facility has a unique objective of making sure that all countries have access to the broadest portfolio of COVID-19 vaccine candidates across a range of technologies, regardless of their ability to pay. It is specifically designed to maximize the chances of success by investing in the development and manufacture of a large number of vaccine candidates at the same time.

As we continue working towards a common shared goal of bringing the pandemic to an end, we must also prepare for the obstacles that we face in reaching vulnerable populations in each corner of the world. This includes manufacturing at risk billions of doses of a yet unknown vaccine thus doubling if not tripling current capacity, as well as preparing for a massive distribution of vaccines that may have unique logistical attributes.


PhRMA [to 26 Sep 2020]
Selected Press Releases, Statements
Growth in innovative, value-based contracts holds promise for the health system and for patients
Katie Koziara   |     September 24, 2020